Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Shares Traded Last Trade
  8.60 0.61% 1,415.40 4,667,934 16:35:23
Bid Price Offer Price High Price Low Price Open Price
1,413.20 1,413.60 1,422.00 1,399.20 1,412.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.00 5,442.00 87.60 16.2 57,569
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:26 O 6,539 1,412.157 GBX

Gsk (GSK) Latest News (1)

More Gsk News
Gsk Investors    Gsk Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 6.62% 2022-05-31

Gsk (GSK) Discussions and Chat

Gsk Forums and Chat

Date Time Title Posts
01/12/202211:28Glaxosmithkline - The recovery31,225
01/9/202214:17GSK - just mucking around3
24/8/202214:27GlazoSmithKline - News & Information136
23/1/202114:27In Rude Health!1

Add a New Thread

Gsk (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-12-01 18:28:271,412.166,53992,340.95O
2022-12-01 18:06:451,407.5816,441231,420.56O
2022-12-01 18:05:201,407.181952,744.00O
2022-12-01 17:59:381,415.4047665.24O
2022-12-01 17:59:381,415.403,26846,255.27O
View all Gsk trades in real-time

Gsk (GSK) Top Chat Posts

Top Posts
Posted at 01/12/2022 08:20 by Gsk Daily Update
Gsk Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,406.80p.
Gsk Plc has a 4 week average price of 1,310.60p and a 12 week average price of 1,283.20p.
The 1 year high share price is 1,824.40p while the 1 year low share price is currently 1,283.20p.
There are currently 4,067,353,132 shares in issue and the average daily traded volume is 10,439,388 shares. The market capitalisation of Gsk Plc is £57,569,316,230.33.
Posted at 30/11/2022 20:22 by geckotheglorious
”GSK is a potential buyout candidate for Novartis - Intron Health”
GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London.

The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology.

In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal.

Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025.
The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition.


Posted at 25/11/2022 08:08 by alibizzle
Roll on.2023 , GSK share price has been a disaster this year . Even with good news it falls
Posted at 11/11/2022 14:42 by geckotheglorious
GSK drops as UBS cuts to Sell on 2027 “bottleneck”

GSK (NYSE:GSK) lost ~4% pre-market Friday after UBS downgraded the British drugmaker to Sell from Hold, questioning the durability of the company’s HIV franchise and revenue from its shingles vaccine Shingrix beyond 2027.

The analysts led by Michael Leuchten estimate a ~20% revenue hit to the company when Shingrix reaches the peak penetration in the U.S. catch-up population in 2027 and HIV therapy dolutegravir faces a patent cliff around the same timeframe.

The analysts think the current consensus for GSK (GSK) fails to recognize the uncertainty over the HIV franchise and implies more than £2B Shingrix revenue than feasible.

The company has time to adjust R&D options and earmark additional capital (£20B – £30B) to tide over the 2027 “bottleneck,” but “this could mean earnings dilution,” the team added, lowering the 12-month price target on GSK (GSK) to 1,300p from 1,820p.


Posted at 03/11/2022 10:12 by anhar
After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods

Not really, that's just the BS they tell you. The real reason for these consolidations following demergers and cash returns is cosmetic and face-saving, ie. to avoid what they see as the shame arising from the price fall that would have to occur without the consol. There's no real need for such consols at all, but I guess they make a few bucks for the advisers.

Posted at 03/11/2022 09:22 by tradermichael
After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods
Posted at 03/11/2022 09:06 by stewart64
I wasn't a holder of GSK on demerger day, so didn't go into the mechanics at that time. But wondered if someone can answer this query please. I understand that 5 shares in old GSK became 4 shares in new GSK. Yet Haleon is worth considerably more than one quarter of new GSK. Therefore why didn't the price of new GSK go down on demerger day? Or did the price adjustment occur later and by what factor.

As I'm assuming comparing the old and new GSK price isn't comparing like with like?

Posted at 02/11/2022 10:24 by tradermichael
The Zantac litigation continues in federal and state courts in the
United States. GSK's position on the scientific validity of these
cases has not changed since the last reporting period. GSK will continue
to defend all claims vigorously.

GSK has been named as a co-defendant in approximately 4,100 filed
personal injury cases in federal and state court. There are approximately
77,000 plaintiffs named in these cases. A significant majority of
these plaintiffs were named in a series of multi-plaintiff complaints
recently filed in Delaware state court and most of these plaintiffs
were previously in the Multidistrict Litigation (MDL) Census Registry
in the Southern District of Florida. They were removed because they
allege a cancer other than the 5 cancers being pursued by the MDL
plaintiffs. In the MDL, plaintiffs originally identified 10 different
types of cancers they wished to pursue. Plaintiffs subsequently dropped
5 of the 10 cancers, and they are proceeding only as to bladder,
esophageal, gastric, liver, and pancreatic, although plaintiffs in
state courts continue to pursue claims beyond the 5 designated cancers.
There are approximately 33,000 unfiled claims relating to GSK and
other co-defendants concerning the 5 designated cancers in the MDL
Census Registry. There are also over 2,000 California state court
cases subject to an agreement between GSK and the plaintiffs which
suspends the statute of limitations to allow the plaintiffs to bring
their claims at a later date. These filed and unfiled counts are
subject to change.

As planned, in September and October 2022, the MDL Court held hearings
on the admissibility of each side's general causation expert witnesses
("Daubert hearings"). Based on the 12 epidemiological studies conducted
looking at human data regarding the use of ranitidine, the scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any type of cancer. The 12th additional
epidemiologic study (Wang et al. (2022)) was recently released. When
comparing ranitidine to an active comparator (famotidine), Wang 2022
found a statistically significant increased risk with regard to liver
cancer (Hazard Ratio 1.22, 95% Confidence Interval 1.06-1.40) and
no statistically significant increased risk for the remaining 4 cancers
pursued in the MDL. Consistency across available epidemiological
evidence, particularly where reported potential associations are
modest, is critical for drawing reliable conclusions about causation.
The parties await a decision from Judge Robin L. Rosenberg.

In the California Zantac litigation Cases JCCP 5150 (JCCP), the Court
will hold a Sargon hearing on 25 January 2023 regarding the admissibility
of expert witnesses, including general causation expert witnesses,
for the first bellwether trials. The first bellwether trial is expected
to start on 13 February 2023 in the California JCCP.

The Illinois Supreme Court recently consolidated all Illinois ranitidine
cases in Cook County for pretrial proceedings with trial dates to
be set, including the previously scheduled Madison County trial.

Given the complex ownership and marketing of Zantac prescription
and over-the-counter (OTC) medicine over many years, numerous claims
involve several defendants. As a result, some defendants have served
one another, including GSK, with notice of potential indemnification
claims about possible liabilities connected particularly with Zantac
OTC. Given the early stage of the proceedings, GSK cannot meaningfully
assess what liability, if any, it may have, nor can it meaningfully
assess the liability of other parties under relevant indemnification

Further information regarding the litigation can be found in GSK's
11 August 2022 and 16 August 2022 statements.

Posted at 28/10/2022 09:44 by netcurtains
Despite this, Broker Shore Capital says there is a “value disconnect” in GSK’s share price. In a note to investors, analyst Dr Susie Jana said with GSK shares trading at 9.9 times 2023 earnings, versus peers at an average of 14.8 times, GSK’s fair value is at £18 per share, suggesting around 32% upside.

Posted at 13/10/2022 18:19 by alibizzle
GSK share price says 1331 here but when I google it it says 1373 ? Also online it says that haleon share price could collapse to 9pence next year so should I sell now ?
Posted at 22/8/2022 09:10 by geckotheglorious
"Clouds are gathering(again) for GSK"
Summary TEL Investment Research

GSK was having a turnaround year, with drugs pipeline strong and H1 results impressive.

Zantac lawsuits are presenting a significant risk to investing in GSK.
Haleon's public offering was underwhelming.


The once blockbuster stress-relief drug of GSK is facing increasingly significant lawsuits in the United States. While the lawsuits have been rolling on for a while, analyst reports by Morgan Stanley and other banks were published over the past days, highlighting significant litigation risks. Morgan Stanley estimated that damages could reach up to USD 45 billion, out of which around 60% would be charged to GSK – about a third of GSK’s market cap, and five times its net income in 2021.


Morningstar Analyst Note | Damien Conover, CFA | Aug 11, 2022
Shares of GSK and Sanofi are under pressure due to increasing concerns regarding legal cases related to a potential cancer side effect from the over-the-counter heartburn medicine Zantac, according to several news sources.

We view the pressure as overdone, as we do not expect major legal settlements regarding the medicine. We are not changing our fair value estimates for the companies as we have already factored in minor payouts related to drug liabilities for both companies.

Also, we do not expect this ongoing litigation to have an impact on the moats of GSK or Sanofi, which are much more related to strong innovation with prescription drugs that should not be affected by the Zantac legal issues.

The implied market capitalization losses for these companies of over $30 billion potentially due to the Zantac legal concerns seems too high. Litigation around drug side effects is not uncommon in the U.S., but a payout amount suggested by the stock price declines at GSK and Sanofi would seem extraordinary. For reference, most drug side-effect settlements range from nothing to low double-digit millions of dollars. The largest drug settlements due to side effects tend to range from $2 billion to $7 billion. However, the opioid settlements for Purdue Pharma, Teva, Johnson & Johnson, and Mallinckrodt totaled close to $20 billion. However, the Zantac issues look less damaging for Sanofi and GSK. While Zantac was removed from the U.S. market close to two years ago due to potential carcinogenic effects, the strong safety profile of the drug in previous decades (drug was launched in 1981) suggests challenging legal hurdles for plaintiffs. Also, other firms have distributed Zantac, which may reduce the legal pressures for GSK and Sanofi.

As far as next steps, we expect Zantac litigation cases to begin later in 2022 and into 2023. We expect a prolonged litigation process as involved companies will likely litigate these cases one by one partly because of the slow legal system.

Gsk share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221202 06:42:14